GLP-1 Pipeline Tracker
The weight-loss and metabolic drugs after semaglutide and tirzepatide: who makes them, how far along they are, and their US status. Each entry links to its dated milestones.
Pipeline
16 drugs tracked
| Drug | Class | Sponsor | Phase | US status | Searches |
|---|---|---|---|---|---|
| Retatrutide | GLP-1/GIP/glucagon triple agonist | Eli Lilly | Phase 3 | Investigational · phase 3 (TRIUMPH) | 823k/mo |
| Orforglipron | Oral small-molecule GLP-1 | Eli Lilly | Approved | FDA approved as Foundayo (1 Apr 2026) | 27k/mo |
| CagriSema | Amylin + GLP-1 combination | Novo Nordisk | Phase 3 | Investigational · filed with FDA | 5.4k/mo |
| Cagrilintide | Amylin analog | Novo Nordisk | Phase 3 | Investigational (CagriSema component) | 33k/mo |
| Survodutide | GLP-1/glucagon dual agonist | Boehringer Ingelheim | Phase 3 | Investigational · phase 3 | 8.1k/mo |
| Mazdutide | GLP-1/glucagon dual agonist | Innovent Biologics; Eli Lilly | Phase 3 | Approved in China; investigational in the US | 5.4k/mo |
| Amycretin | GLP-1/amylin unimolecular agonist | Novo Nordisk | Phase 3 | Investigational | 880/mo |
| MariTide | GLP-1 agonist / GIPR antagonist antibody-peptide | Amgen | Phase 3 | Investigational | 1.6k/mo |
| Eloralintide | Amylin agonist | Eli Lilly | Phase 3 | Investigational | |
| Pemvidutide | GLP-1/glucagon dual agonist | Altimmune | Phase 3 (MASH) | Investigational | 720/mo |
| VK2735 | GLP-1/GIP dual agonist | Viking Therapeutics | Phase 3 | Investigational | |
| Petrelintide | Amylin analog | Zealand Pharma / Roche | Phase 3 (registered, not yet recruiting) | Investigational | 720/mo |
| Ecnoglutide | GLP-1 agonist | Hangzhou Sciwind Biosciences | Phase 3 | Investigational | 390/mo |
| Efinopegdutide | GLP-1/glucagon dual agonist (MASH) | Merck Sharp & Dohme | Phase 2 | Investigational | |
| Dapiglutide | GLP-1/GLP-2 dual agonist | University Hospital, Gentofte, Copenhagen | Phase 2 | Investigational | |
| Bimagrumab | Activin receptor antibody (muscle-sparing) | Eli Lilly (earlier trials: Novartis) | Phase 2 (obesity) | Investigational |
Phase and sponsor come from public company and regulator records. Bracketed values are pending a source. Searches are US monthly Google searches for the drug name.